Guardant Health
GH
$98.47
-1.47%
Guardant Health is a leader in the development and commercialization of liquid biopsy tests for cancer detection and monitoring, operating within the Medical Diagnostics & Research industry. The company is a pioneer and market leader in non-invasive blood-based genomic profiling, primarily through its flagship Guardant360 test for advanced cancer, while expanding into early detection with its Shield colorectal cancer screening test. The current investor narrative is intensely focused on the company's transition from a high-growth, high-burn diagnostic provider to a path toward profitability, with recent quarterly results showing significant revenue growth but ongoing losses, and the market is closely watching for progress in reimbursement and adoption of its screening portfolio.…
GH
Guardant Health
$98.47
Related headlines
Investment Opinion: Should I buy GH Today?
Rating: Hold. The core thesis is that Guardant Health possesses a disruptive technology and strong growth trajectory, but these are fully priced in alongside significant execution and financial risks that warrant caution. Supporting Evidence: The stock trades at a premium Price-to-Sales ratio of 13.04 (EV/Sales 12.15), which is high for the sector but below its own historical peak of 46.72, indicating de-rating. Revenue growth is robust at 39.37% YoY, and analyst consensus is unanimously bullish, projecting a turnaround to $2.40 EPS. However, profitability metrics are deeply negative (Operating Margin -42.95%, Net Margin -45.68%), and cash burn is severe with -$220.78M TTM FCF. The implied upside is contingent on flawless execution of the analyst forecast. Risks & Conditions: The two biggest risks are 1) the failure to achieve operating leverage and stem cash burn, and 2) a slowdown in revenue growth that invalidates the premium valuation. This Hold rating would upgrade to a Buy if the company demonstrates consecutive quarters of operating margin improvement toward breakeven or announces a major reimbursement win for Shield. It would downgrade to a Sell if quarterly revenue growth decelerates below 25% or if cash burn accelerates. Relative to its own compressed history and growth profile, the stock appears fairly valued, but it remains overvalued on a pure profitability basis.
Sign up to view all
GH 12-Month Price Forecast
Guardant Health is a high-risk, high-potential story at an inflection point. The neutral stance reflects the balance between its undeniable leadership in a transformative market and the precarious financial reality of deep, ongoing losses. The base case (55% probability) of continued growth with slow margin improvement is most likely, aligning the stock with analyst revenue targets but lacking a near-term catalyst for multiple re-expansion. Confidence is medium due to the high volatility (beta 1.65) and binary nature of upcoming reimbursement decisions. The stance would upgrade to bullish on evidence of sustained operating margin improvement or a major commercial win for Shield. It would turn bearish on any material deceleration in revenue growth or an acceleration in cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Guardant Health's 12-month outlook, with a consensus price target around $128.01 and implied upside of +30.0% versus the current price.
Average Target
$128.01
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$79 - $128
Analyst target range
Analyst coverage for Guardant Health is substantial, with 6 firms providing estimates and a clear pattern of institutional ratings showing strong bullish sentiment; recent actions from 10 major firms in February 2026 were unanimously positive, including 'Buy', 'Overweight', and 'Outperform' ratings, with no downgrades. The consensus leans heavily bullish, with an average revenue estimate for the forward period of $3.07 billion, implying significant growth from the current ~$1.1 billion annual run-rate, and an average EPS estimate of $2.40, signaling analyst expectation for a sharp turnaround to profitability. The target price range is not explicitly provided in the data, but the high level of institutional support and specific revenue/eps estimates indicate a wide range of potential outcomes. The high-end estimates, such as revenue of $3.24 billion and EPS of $2.57, likely assume successful commercial execution, expanding margins, and strong adoption of the screening portfolio. The low-end estimates still project growth to $3.01 billion in revenue, but may bake in more conservative assumptions on reimbursement and competitive dynamics. The tight clustering of recent analyst actions (all reiterations in February 2026) suggests strong, though not necessarily new, conviction in the story, but the stock's recent price decline indicates the market is questioning this optimism.
Bulls vs Bears: GH Investment Factors
The investment thesis for Guardant Health is a classic battle between compelling top-line growth and a troubling bottom-line reality. The bull case, currently supported by strong analyst conviction, rests on the company's market leadership and accelerating 39% revenue growth paving a path to the projected $2.40 EPS profitability. The bear case, evidenced by the stock's severe technical breakdown and valuation compression, focuses on unsustainable cash burn (-$220M TTM FCF) and a negative equity base. The bear side currently has stronger near-term evidence, as the market is actively punishing the stock for its lack of profitability despite growth. The single most important tension is the timing and certainty of the transition to profitability. If Guardant can demonstrate accelerating operating leverage and a credible path to positive cash flow, the bull thesis will be validated. If losses persist or widen, the high valuation multiple will collapse further.
Bullish
- Robust Revenue Growth: Q4 2025 revenue grew 39.37% year-over-year to $281.27 million, accelerating from sequential quarterly increases. This demonstrates strong commercial traction across its core Oncology test business ($189.95M) and emerging Screening segment ($35.13M).
- Analyst Consensus Bullish: Analyst sentiment is unanimously positive, with 10 major firms reiterating 'Buy' or equivalent ratings in February 2026. They project a sharp turnaround to profitability with an average forward EPS estimate of $2.40 and revenue of $3.07 billion, implying significant growth from the current run-rate.
- Strong Gross Margins: The company maintains healthy gross margins of 64.63% (Q4 2025), consistent with its trailing gross margin of 64.46%. This indicates sound underlying test economics and provides a foundation for future operating leverage as revenue scales.
- Market Leadership in Liquid Biopsy: Guardant is a pioneer and leader in the high-growth liquid biopsy market for cancer detection. Its first-mover advantage and expanding test portfolio (Guardant360, Shield) position it to capture a large total addressable market, justifying a premium valuation.
Bearish
- Severe Cash Burn & Unprofitability: The company is deeply unprofitable with a Q4 2025 net loss of $128.49M and trailing free cash flow of -$220.78M. Operating expenses at 107.6% of revenue far outpace gross profit, raising sustainability concerns and the need for future capital raises.
- Valuation Compression & Technical Downtrend: The stock is in a severe downtrend, down 23.18% over 3 months and underperforming the S&P 500 by -27.32%. Its PS ratio has compressed sharply from 46.72 to 13.04, reflecting a market de-rating due to profitability concerns and high volatility (beta of 1.65).
- Negative Shareholder Equity: Accumulated deficits have eroded shareholder equity to a negative $99.3 million, resulting in a nonsensical debt-to-equity ratio of -16.94 and a price-to-book ratio of -128.95. This weak balance sheet structure heightens financial risk.
- High Valuation Premium: Despite the compression, a trailing PS ratio of 13.04 and EV/Sales of 12.15 remain elevated for the diagnostics industry. This premium prices in near-perfect execution on screening adoption and reimbursement, leaving no margin for error.
GH Technical Analysis
The stock is in a pronounced downtrend from its recent highs, trading at $87.60, which is approximately 73% of its 52-week range between $36.36 and $120.74. Despite a strong 1-year gain of 79.25%, the stock has experienced a severe correction, with a 23.18% decline over the past 3 months and a 3.89% drop in the last month, indicating that long-term strength has given way to significant near-term selling pressure. This divergence suggests a potential trend reversal or a deep consolidation phase after the prior rally, with the stock's relative strength versus the S&P 500 deeply negative at -27.32 over 3 months, confirming pronounced underperformance. Recent momentum is decisively negative, with the stock down 23.18% over 3 months and 3.89% over 1 month, starkly contrasting with the S&P 500's gains of 4.14% and 9.98% over the same periods, respectively. This severe underperformance, evidenced by relative strength figures of -27.32 (3-month) and -13.87 (1-month), signals accelerating bearish momentum and a loss of investor confidence, likely driven by concerns over persistent losses and cash burn despite strong revenue growth. Key technical support is at the 52-week low of $36.36, while immediate resistance is at the 52-week high of $120.74. A breakdown below the recent trading range lows near $78.60 (from April 10) could signal a test of lower support levels, while a recovery above the $100-$105 zone would be needed to suggest the downtrend is abating. The stock's beta of 1.65 indicates it is 65% more volatile than the broader market, which amplifies both upside and downside moves and necessitates larger position-sizing considerations for risk management.
Beta
1.49
1.49x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$36-$121
Price range past year
Annual Return
+138.1%
Cumulative gain past year
| Period | GH Return | S&P 500 |
|---|---|---|
| 1m | +19.8% | +8.2% |
| 3m | -4.2% | +9.0% |
| 6m | +4.3% | +10.5% |
| 1y | +138.1% | +26.5% |
| ytd | -3.2% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GH Fundamental Analysis
Guardant Health's revenue trajectory is robust and accelerating, with Q4 2025 revenue of $281.27 million representing a 39.37% year-over-year growth rate. This growth has been consistent, with sequential quarterly revenue increases from $203.47 million in Q1 to $281.27 million in Q4 2025. The revenue segment data shows Oncology tests ($189.95 million) as the primary driver, followed by Biopharma & Data ($54.01 million) and Screening ($35.13 million), indicating the core business is firing on all cylinders and the early detection opportunity is beginning to contribute meaningfully. The company remains deeply unprofitable, with a Q4 2025 net loss of $128.49 million and an EPS of -$1.00, though the net margin of -45.68% shows an improvement from -55.00% in Q4 2024. Gross margins are healthy at 64.63% in Q4 2025, consistent with the 64.46% trailing gross margin, indicating the underlying test economics are sound, but operating expenses at $302.58 million (107.6% of revenue) continue to far outpace gross profit, leading to an operating margin of -42.95%. The balance sheet shows a strong current ratio of 4.84, indicating ample short-term liquidity, but the financial health is challenged by significant cash burn. Trailing twelve-month free cash flow is deeply negative at -$220.78 million, and the latest quarterly operating cash flow was -$14.08 million. The debt-to-equity ratio is a negative -16.94, an artifact of accumulated deficits eroding shareholder equity, which stood at a negative $99.3 million as implied by the market cap and price-to-book ratio. The company's return on equity of 4.19% is positive but misleading due to the negative equity base, while return on assets is a poor -15.59%, reflecting inefficient use of assets to generate profits.
Quarterly Revenue
$281266000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$-220777000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GH Overvalued?
Given the company's consistent net losses (Net Income ≤ 0), the primary valuation metric selected is the Price-to-Sales (PS) ratio. Guardant Health trades at a trailing PS ratio of 13.04 and an Enterprise Value-to-Sales (EV/Sales) of 12.15. The absence of a forward PE (reported as -125.61) underscores the market's expectation that profitability remains years away, with the valuation entirely hinged on sales growth and future margin potential. Compared to industry averages, a PS ratio of 13.04 is elevated for a diagnostics company, typically commanding a premium for its disruptive technology and high growth profile. The premium reflects investor belief in the large total addressable market for liquid biopsies and Guardant's first-mover advantage, but it also prices in significant future success in screening adoption and reimbursement, leaving little room for execution missteps. Historically, the stock's current PS ratio of 13.04 is below its own recent historical range; for instance, it traded at a PS of 46.72 at the end of Q4 2025 when the price was higher. This sharp compression from the top of its historical band suggests the market has significantly de-rated the stock due to concerns over the path to profitability and cash burn, moving it from a premium growth narrative toward a more risk-averse valuation that demands evidence of operational leverage.
PE
-30.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -35x~-4x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-37.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's unsustainable cash burn. With trailing free cash flow of -$220.78 million and operating expenses consuming 107.6% of revenue, Guardant is reliant on external financing to fund operations. The negative shareholder equity (-$99.3M implied) and nonsensical debt-to-equity ratio (-16.94) indicate a weak balance sheet structure that could limit financial flexibility. Revenue, while growing, remains concentrated in its core Oncology tests ($189.95M in Q4), making the successful commercialization of its Shield screening test critical to diversifying the growth engine. Market & Competitive Risks include significant valuation compression risk. The stock's PS ratio has already fallen from 46.72 to 13.04, but it remains at a premium to typical diagnostics peers, trading on future promise. Any delay in reimbursement for its screening tests or increased competition in the liquid biopsy space could trigger further multiple contraction. The stock's high beta of 1.65 makes it 65% more volatile than the market, amplifying downside during sector-wide sell-offs or risk-off environments, as seen in its -27.32% relative underperformance over the last three months. Worst-Case Scenario involves a 'growth stall' combined with a funding crisis. If revenue growth decelerates meaningfully below current 39% levels while losses remain wide, the market could completely lose faith in the profitability timeline. This could lead to a failed capital raise, forcing drastic cost-cutting that cripples growth initiatives. In this adverse scenario, the stock could re-test its 52-week low of $36.36, representing a downside of approximately -58% from the current price of $87.60. A more realistic bear-case target might align with a further de-rated PS multiple on stalled growth, suggesting a potential downside of -35% to -50%.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company burns significant cash (-$220M TTM FCF) and has negative shareholder equity, raising concerns about future dilution or financing difficulties. 2) Execution Risk: The premium valuation hinges on successful commercialization and reimbursement for its Shield screening test; any delay could crater the stock. 3) Competitive & Market Risk: The liquid biopsy space is attractive and may draw increased competition, while the stock's high beta (1.65) makes it vulnerable to market downturns. 4) Profitability Risk: There is no guarantee the company can achieve the operating leverage needed to reach the analyst-projected profitability.
The 12-month forecast for GH is bifurcated, with a base case target range of $90-$110 (55% probability), a bull case of $120-$140 (25% probability), and a bear case of $50-$70 (20% probability). The base case, which is most likely, assumes continued strong revenue growth but only gradual improvement in heavy losses, leading to range-bound trading. The forecast hinges almost entirely on the company's ability to demonstrate progress toward profitability. The key assumption behind the base case is that revenue growth remains above 30% while operating margins slowly improve from the current -42.95%.
GH's valuation is complex and context-dependent. On a pure sales basis, its Price-to-Sales ratio of 13.04 is elevated compared to mature diagnostics companies, suggesting overvaluation. However, relative to its own historical PS ratio of 46.72, it appears to have undergone a significant de-rating. The market is currently valuing GH as a high-growth story with unresolved profitability, which is a fair assessment. The valuation implies the market expects successful execution on its screening portfolio and a credible path to the analyst-projected $2.40 EPS. Therefore, it is fairly valued given its growth profile but remains expensive on any fundamental metric involving earnings.
GH is a high-risk, high-reward investment that is not a good buy for all investors. For aggressive growth investors comfortable with volatility and multi-year time horizons, the stock offers exposure to a leading disruptor in cancer diagnostics with 39% revenue growth. However, the unanimous analyst 'Buy' ratings are counterbalanced by severe cash burn (-$220M TTM FCF) and a recent 23% price decline, indicating significant skepticism. It could be a good buy for those who believe in the management's ability to execute on the path to profitability, but it is a speculative hold for most.
GH is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. The company is in a capital-intensive growth phase, and the investment thesis will only be proven over multiple years as it scales its screening business and moves toward profitability. Its high beta of 1.65 and lack of dividends make it unsuitable for income or low-volatility portfolios. Short-term trading is extremely risky due to the stock's volatility and sensitivity to quarterly earnings reports and regulatory news. Only investors with a long-term horizon who can withstand significant interim volatility should consider a position.